JP2020512361A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512361A5
JP2020512361A5 JP2019553224A JP2019553224A JP2020512361A5 JP 2020512361 A5 JP2020512361 A5 JP 2020512361A5 JP 2019553224 A JP2019553224 A JP 2019553224A JP 2019553224 A JP2019553224 A JP 2019553224A JP 2020512361 A5 JP2020512361 A5 JP 2020512361A5
Authority
JP
Japan
Prior art keywords
antibody
complex
molecule
combination
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512361A (ja
Filing date
Publication date
Priority claimed from US15/937,493 external-priority patent/US20190048055A1/en
Application filed filed Critical
Publication of JP2020512361A publication Critical patent/JP2020512361A/ja
Publication of JP2020512361A5 publication Critical patent/JP2020512361A5/ja
Pending legal-status Critical Current

Links

JP2019553224A 2017-03-31 2018-03-30 癌治療のために抗ｃｄ３８抗体と併用したａｌｔ−８０３ Pending JP2020512361A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762480339P 2017-03-31 2017-03-31
US62/480,339 2017-03-31
US15/937,493 US20190048055A1 (en) 2017-03-31 2018-03-27 Alt-803 in combination with anti-cd38 antibody for cancer therapies
US15/937,493 2018-03-27
PCT/US2018/025366 WO2018183821A1 (en) 2017-03-31 2018-03-30 Alt-803 in combination with anti-cd38 antibody for cancer therapies

Publications (2)

Publication Number Publication Date
JP2020512361A JP2020512361A (ja) 2020-04-23
JP2020512361A5 true JP2020512361A5 (https=) 2021-04-30

Family

ID=63678335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553224A Pending JP2020512361A (ja) 2017-03-31 2018-03-30 癌治療のために抗ｃｄ３８抗体と併用したａｌｔ−８０３

Country Status (9)

Country Link
US (1) US20190048055A1 (https=)
EP (1) EP3601363B1 (https=)
JP (1) JP2020512361A (https=)
KR (1) KR102748188B1 (https=)
CN (1) CN110494449B (https=)
AU (1) AU2018243550B2 (https=)
CA (1) CA3058427C (https=)
TW (1) TW201841651A (https=)
WO (1) WO2018183821A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865230B2 (en) 2016-05-27 2020-12-15 Altor Bioscience, Llc Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102867975B1 (ko) 2017-03-06 2025-10-14 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
JP2023502712A (ja) * 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
KR102692667B1 (ko) 2020-11-17 2024-08-06 고려대학교 산학협력단 면역치료요법의 효능, 예후, 또는 내성 예측을 위한 바이오마커, 및 면역치료요법의 효능 증진을 위한 표적으로서 tctp의 용도
CN113293191A (zh) * 2021-05-28 2021-08-24 山东大学齐鲁医院 Gfp转染肿瘤细胞的方法在检测肿瘤相关巨噬细胞吞噬功能中的应用
WO2023178253A2 (en) * 2022-03-18 2023-09-21 Igm Biosciences, Inc. Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
GB202315149D0 (en) 2023-10-03 2023-11-15 Celleron Therapeutics Ltd Combination therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
US8507A (en) 1851-11-11 petess
US222A (en) 1837-06-10 Truss for the retention and radical cure qe hernia
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7213961B2 (en) 2003-07-11 2007-05-08 Hubbell Incorporated Low voltage luminaire assembly
KR101131297B1 (ko) 2003-11-10 2012-03-30 알토 바이오사이언스 코포레이션 가용성 티씨알 분자 및 이용 방법
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
US8507222B2 (en) * 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN104379169A (zh) * 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
US20150359853A1 (en) * 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
KR102762243B1 (ko) * 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3359157A4 (en) * 2015-10-06 2019-05-15 The Wistar Institute Of Anatomy And Biology METHOD AND COMPOSITIONS FOR THE TREATMENT OF METASTASIVE AND REFRACTORY CANCER DISEASES AND TUMORS

Similar Documents

Publication Publication Date Title
JP2020512361A5 (https=)
EP2944323B1 (en) Agents for treating tumours, use and method thereof
JP2019515888A5 (https=)
JP2019516748A5 (https=)
JP2021525735A5 (https=)
WO2014142220A1 (ja) 抗腫瘍剤
JP2021535149A5 (https=)
JP2015517511A5 (https=)
US20200377596A1 (en) Dosing of bispecific t cell engager
EP3972609B1 (en) Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release
JP2020510011A5 (https=)
CN102935228B (zh) 用于肿瘤治疗的试剂、其用途及方法
EP4319815A1 (en) Dosing of bispecific t cell engager
JP2013543869A5 (https=)
Sylvan et al. Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
JP7098518B2 (ja) 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたナチュラルキラー細胞およびその使用
JP2016104703A (ja) 抗腫瘍剤
JP2023536596A5 (https=)
Zhang et al. PF299 EARLY RESPONSE OBSERVATION OF PEDIATRIC PATIENTS WITH BURKITT'S LYMPHOMA TREATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
Sun et al. Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma
US20150342925A1 (en) Use of antioxidants as an adjuvant to immune stimulators to augment tumor immunity and prevent toxicity associated with oxidative stress
Zent Monoclonal antibody therapy in chronic lymphocytic leukemia
JP2022058481A (ja) 癌の治療に関する抗ｆｕｇｅｔａｃｔｉｃ特性を有する組成物
Lyu et al. hematologic toxicity post-CD19
TW202517679A (zh) 以抗ｉｌｔ２抗體治療癌症